The Student Movement Volume 107 Issue 17: I Dreamed a Dream : AU One Day Closer to Spring

HUMANS Joyful Resilience: An Interview with Artist Jasmin Hislop, Interviewed by Solana Campbell Love is in the Air, Interviewed by Grace No Working at the Writing Center: Interview With Camilia Howell, Interviewed by Gloria Oh Arts & Entertainment Blackventist Praise, Nathaniel Reid Ceramics: Revival of the Art Elective, Ysabelle Fernando Currently: The Romantics, Solana Campbell Freedom: a Black History Month Playlist, Amelia Stefanescu NEWS Dinosaurs Under the Microscope: Mary Higby Schweitzer Visits Andrews, Alannah Tjhatra Les Misérables at the Chicago Cadillac Palace Theatre, Gloria Oh IDEAS Engineering What We Eat: The Past, Present, and Future of Genetically Modified Food, Alexander Navarro Russia and Ukraine: New Year, New Direction?, Melissa Moore Stress and Video Games, Rachel Ingram-Clay PULSE Can Political Parties Be Inherently Christ-Like?, Wambui Karanja Is Honors an Advantage to our Students?, Melissa Moore The Wellness Center Happenings, Lexie Dunham LAST WORD Why Read? Practice Makes Better. Terika Williamshttps://digitalcommons.andrews.edu/sm-107/1016/thumbnail.jp

The Student Movement Volume 107 Issue 13: We\u27ve Got the Spirit: Students Celebrate Dr. Luxton

HUMANS Best of Bon Appetit, Nora Martin Interview with the Dean of Lamson and Meier Halls, Interviewed by: Grace No The Joy of Japan, Interviewed by: Gloria Oh ARTS & ENTERTAINMENT A Creation Adventure, Nathaniel Reid Currently: Velma, Solana Campbell Suite Dreams for Sweet Dreams, Skylor Stark Where do I Find God? Part II, Anonymous NEWS AUSA Celebrates 100 Years of Student-Led Action, Andrew Francis Response to A House Divided Story, Christon Arthur, Provost Where\u27s the Harm in True Crime?. Abigail Kim IDEAS Redefining Free Agency in Sports, Andrew Francis Flying Cars of 2030, Rachel Ingram-Clay The Spooky Nature of Our Physical World, Alexander Navarro The State of AI, Abby Shim PULSE Debunking Myths Surrounding J.N. Andrews Honors Program, Gloria Oh Our Dear AU: A Spirit Week Tour, Lexie Dunham Romance and Reading, Gloria Oh LAST WORD An Ode to Tea, Alexander J. Hesshttps://digitalcommons.andrews.edu/sm-107/1012/thumbnail.jp

The Student Movement Volume 107 Issue 2: We Prayed, We Changed, We Glowed: Week Three at Andrews University

HUMANS Change Day Interview: Jessica Bowen, Interviewed by: Gloria Oh Interview with Brandon Alvarez, Interviewed by: Grace No Meet Andrew Rappette, AUSA Executive Vice President, Interviewed by: Lauren Kim ARTS & ENTERTAINMENT Change Day: Art as a Service, Skyler Campbell Currently..., Solana Campbell Disney\u27s D23 Expo Concludes, Andrew Francis In the Rick of Time: Season 6 Launces Off My 2022 School Year, Grace No NEWS Almost Anything Goes, Glow Edition, Yoel Kim & Editors Lead Levels in Benton Harbor, Abigail Kim Students React to Queen Elizabeth\u27s Passing, Andrew Francis IDEAS iOS 16 and the new iPhone: Bop or Flop?, Rachel Ingram-Clay Meghan Markle and the British Media, Terika Williams The Little Mermaid and the Importance of Representation, Genevieve Prouty PULSE Change Day 2022, Elizabeth Dovich Clubs & Organizations Ice Cream Fair, Charisse Lapuebla Scientists Engaging Beyond Classroom & Lab, Desmond Hartwell Murray Divine Direction: Week of Prayer at Andrews University, Melissa Moore LAST WORD Thoughts at 30,000 Feet, Alannah Tjhatrahttps://digitalcommons.andrews.edu/sm-107/1001/thumbnail.jp

The Student Movement Volume 107 Issue 6: Night Market Lights Up Andrews Campus

HUMANS Meet Franky Paypa, AUSA Executive Secretary, Interviewed by: Lauren Kim Meet 19-Year-Old Female CS Major: Andrea Stanko, Interviewed by Kavya Mohanram Meet Jaden Leiterman, AFIA President, Interviewed by: Nora Martin ARTS & ENTERTAINMENT WAUS: A Michiana Music Oasis, Aiko J. Ayala Rios Conductor Profile: Dr. Marc Élysée, Wambui Karanja Currently..., Solana Campbell That\u27s What I Like! The Essential Filipino Jam Playlist, Bella Hamann NEWS Community Engagement Initiative Celebrates Third Year, Scott Moncrieff Illegal Exports: Why Mexico is Suing US Arms Dealers, Julia Randall KASA x SASA Night Market, Alannah Tjhatra IDEAS DeFINE Chapel: A Proposition, Bella Hamann Docuseries: To Love or to Hate?, Abigail Shim For the Love of Food: A Celebration of Filipino American Cuisine, Rachel Ingram-Clay PULSE A Guide to Worship in Berrien Springs, Zothile Sibanda Help Me! How To Survive The Mid-Semester Crisis, Amelia Stefanescu Students Speak on Co-Curricular Credits, Wambui Karanja The Gazebo\u27s Post-Covid Makeover, Melissa Moore LAST WORD The Meaning of Student Movement , Alannah Tjhatrahttps://digitalcommons.andrews.edu/sm-107/1005/thumbnail.jp

The Student Movement Volume 107 Issue 11: Have a Merry Christmas! XOXO, The Student Movement

HUMANS Coping with Finals, Solana Campbell Meet Jea Erazo, AUSA Public Relations Officer. Interviewed by: Caryn Cruz Remembering Sharon Dudgeon, Grace No Women in STEM: Olivia Joyce, Interviewed by: Gloria Oh ARTS & ENTERTAINMENT Football Sunday, Nathaniel Reid, Skylor Stark Student Picks: Christmas Classics, Ysabelle Fernando NEWS AFIA x MLS Christmas Party, Ceiry Flores Boycotts and Bans at the Qatar World Cup, Hannah Cruse In Loving Memory of Seth Williams, Gloria Oh IDEAS How Do We Address Queer Violence?, Alexander J. Hess Is Reality Really Real When You Aren\u27t Really Looking?, Alexander Navarro Reflecting on Christmas Traditions, Rachel Ingram-Clay The New Era of Book Bans, Elizabeth Getahun Why is Everyone so Happy During Christmastime?, Kayla-Hope Bruno PULSE Bon Appétit and the Threat to Cultural Autonomy, Wambui Karanja It\u27s OrnaMEANT to be a Wonderful Christmastime, Lexie Dunham It\u27s the Most Stressful Time of the Year, Reagan McCain Qatar Controversy: The Shadow Behind the World Cup, Melissa Moore Reflections on the Semester and Plans for Break, Elizabeth Dovich LAST WORD A Student Movement Christmas, The Student Movement Staffhttps://digitalcommons.andrews.edu/sm-107/1010/thumbnail.jp

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation